Report: L’Oréal to expand Kiehl’s in U.K.
NEW YORK — L’Oréal is looking to spread its Kiehl’s skin care brand across the United Kingdom this year, according to a published report in The Telegraph.
Kiehl’s opened its first of 15 U.K. locations back in 2002 and now plans to open 12 more stores across the U.K. this year, according to the article.
Founded in 1851 as an apothecary business in New York, Kiehl’s has established a unique reputation in the prestige cosmetics market. The New York brand sold to L’Oréal in 2000 and the French beauty giant has since taken Kiehl’s from its East Village base in New York to 177 stores and 554 outlets worldwide.
Kinerase to donate percentage of sales at Ulta via ‘Change Your Skin, Change Your Life’ campaign
BRIDGEWATER, N.J. — Kinerase, a division of Valeant Pharmaceuticals North America, has announced its second annual "Change Your Skin, Change Your Life" campaign, for which it will partner with four charities throughout the year to make financial contributions.
Each quarter, Kinerase will partner with a different charity, donating 20% of the proceeds of the sales of a selected product. In recognition of American Heart Month this February, Kinerase has chosen to partner with HealthyWomen, an organization whose core mission is to educate, inform and empower women to make smart health choices. The donation will consist of 20% of the proceeds from sales of Kinerase C8 Peptide Intensive Treatment at Ulta during this one-month period.
"’Change Your Skin, Change Your Life’ is not just about bringing the consumer closer to our brand, but also drawing attention to the HealthyWomen organization," stated Jill Wittenberg, marketing manager for Valeant Pharmaceuticals. "We chose HealthyWomen because it shares our goal of keeping women healthy from the inside out. While Kinerase helps protect the outside, HealthyWomen encourages women to protect the inside by giving them the necessary tools to lead healthy lifestyles. Starting with protecting their skin, a simple purchase enables consumers to help protect the lives of women."
Kinerase and Valeant Pharmaceuticals will announce an additional three charitable partners in the "Change Your Skin, Change Your Life" campaign throughout the year.
J&J names successor to CEO
NEW BRUNSWICK, N.J. — Johnson & Johnson on Tuesday named Alex Gorsky CEO of the company, effective April 26, the date of the company’s annual meeting of shareholders. Gorsky also has been nominated for election to the board of directors at the meeting.
Gorsky, 51, currently vice chairman of the company’s executive committee with responsibility for the medical devices and diagnostics group, global supply chain, healthcare compliance, and privacy and government affairs and policy, succeeds Bill Weldon, who has served as chairman and CEO of Johnson & Johnson since 2002. Weldon remains chairman.
As CEO, Gorsky will assume full management responsibilities for Johnson & Johnson, including those currently reporting to him and to Weldon. As vice chairman of the executive committee, Sheri McCoy will report to Gorsky when he assumes the role of CEO. She will continue to lead the pharmaceuticals and consumer groups, and maintain responsibility for information technology.
“This succession decision involved a rigorous, thorough and formal multi-year process, which included consideration of two superbly qualified internal candidates, as well as outside candidates," Weldon stated.
Jim Cullen, the independent presiding director of the Board of Directors, added: “It is a testament to the leadership development and succession planning process at Johnson & Johnson that Mr. Gorsky, like all of the previous chief executives in the Company’s 126-year history, was appointed from within the organization.”
Gorsky began his Johnson & Johnson career in 1988 as a sales representative with Janssen Pharmaceutica. Over the next 15 years, he advanced through positions of increasing responsibility in sales, marketing and management. In 2001, he was appointed president of Janssen, and in 2003, promoted to company group chairman of Johnson & Johnson’s pharmaceuticals business in Europe, the Middle East and Africa.
He left the company in 2004 to join the Novartis Pharmaceuticals Corporation, where he served as head of the company’s pharmaceuticals business in North America. Four years later, he returned to Johnson & Johnson as company group chairman and worldwide franchise chairman for Ethicon in the medical devices business. In 2009, he was appointed worldwide chairman of the surgical care group and to the Johnson & Johnson executive committee. He was appointed vice chairman of the executive committee in January 2011.
Gorsky holds a Bachelor of Science degree from the U.S. Military Academy at West Point, and spent six years in the U.S. Army. In 1996, he earned a Master of Business Administration degree from the Wharton School of the University of Pennsylvania.